hAPOC3
모델명
C57BL/6JSmo-Apoc3tm1(hAPOC3)Smoc
카탈로그
NM-HU-225050
모델 상태
Repository Live
유전자 요약
Gene Symbol
Apoc3
모델 설명
검증 데이터
Fig1. Detection of APOC3 expression in liver by RT-PCR.
Wild type: only one band at 196 bp with primers F1/R1(mApoc3);
Homozygous: only one band at 219 bp with primers F2/R2(hAPOC3).
Abbr. M, DNA marker; HO, homozygous; WT, wild type.
Fig2. Detection of species-specific APOC3 expression in serum by ELISA.
Abbr. HO, homozygous; HE, heterozygous; WT, wild type.
Fig3. Monitoring of blood lipids levels in hAPOC3 mice (n=3 female and 3 male).
Abbr. Hom, homozygous; WT, wild type.
Fig4. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Blood lipids level of hAPOC3 mice before or after dosing were detected. Compared to vehicle, ARO-APOC3 treatment group showed a decrease in TG, T-CHO and LDL-C. Mean ± SEM. t-test, *P < 0.05, ***P < 0.001.
Fig5. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. At day 29 post-dosing, the mice were euthanized, and their livers were collected for the assessment of human APOC3 mRNA expression via qPCR. The results indicated a significant reduction in human APOC3 expression in the ARO-APOC3 treatment group compared to the vehicle control. Mean ± SEM. t-test.
Fig6. In Vivo Efficacy of APOC3 RNAi (ARO-APOC3) in hAPOC3 Mice.
hAPOC3 mice (male, 13 weeks old) were randomly divided into two groups(n=5/group). Mice were administered with ARO-APOC3, a nucleic acid drug targeting hAPOC3, synthesized according to the relevant patents. Expression level of hAPOC3 before or after dosing at indicated timepoint was detected by ELISA. Compared to vehicle, ARO-APOC3 treatment group showed a significant decrease in the expression of hAPOC3. Mean ± SEM. t-test, ***P < 0.001
당신은 또한 좋아할 수 있습니다
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
조회Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
조회Milestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
조회